Azmi is an Entrepreneur-in-Residence on the Life Sciences team and highly experienced in drug development across a broad range of therapeutic areas.
Azmi joined Frazier in 2019 as Entrepreneur-in-Residence. He is also Chief Operating Officer and co-founder of Phathom Pharmaceuticals, a Frazier-founded company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders.
Azmi is the former deputy chief medical and scientific officer and head of global development at Takeda Pharmaceuticals. In these roles, he led all global R&D medical, regulatory, operations, and data analytics functions. In addition, he led the R&D strategic areas of portfolio management and planning, focusing on enhancing the pipeline and productivity.
During his 14-year career at Takeda in the U.S. and Japan, Azmi has overseen global drug development for both early and late stage agents, bringing the majority of Takeda’s 21 new drugs in multiple therapeutic areas and countries to market. He is also responsible for the design and execution of the company’s major R&D transformation utilizing industry leading approaches to drive innovation. Azmi has led or directed partnerships and alliances in gastroenterology, central nervous system, oncology, immunology, and cardiovascular medicine and metabolism.
Prior to Takeda, Azmi held leadership positions at Abbott Laboratories, including venture head of immunology and oncology ventures.
Azmi has an M.D. from Ain-Shams University, Cairo, Egypt, and an M.P.H. from the University of Minnesota.